Cyclopharm Limited
Cyclopharm Limited is an Australia-based radiopharmaceutical company.
The business
Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its Technegas product is a broad-spectrum diagnostic lung imaging technology for visualization of pulmonary ventilation and lung function. It includes the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. Company distributes its products in approximately 65 countries.
Small Caps Research
No research on Cyclopharm Limited yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise CYC based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Cyclopharm granted maximum US market patent extension for Technegas imaging kit
Cyclopharm (ASX: CYC) has gained further momentum in its strategy to grow sales of its Technegas kit in the US after being granted an extension to its patent there. The new United States Patent and Trademark Office (USPTO) approval provides for the maximum patent term extension allowable of five years, covering the Technegas kit to […]
Cyclopharm secures major US deal to deploy Technegas products across HCA network
Radiopharmaceutical company Cyclopharm (ASX: CYC) has signed a contract to deploy its flagship product Technegas in as many as 169 nuclear medicine departments across the Hospital Corporation of America Healthcare (HCA) suite of facilities. The three-year contract marks a significant milestone for the company, as HCA operates one of the most comprehensive medical networks in […]
Diagnostic imaging: which stock will become the next Pro Medicus?
For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee problem of irradiating the patients. And that’s because they are cheap and convenient. The underlying tech hasn’t really moved on since 1895, when […]
Cyclopharm set to take the fight against asthma to the next level via Technegas
Radiopharmaceutical company Cyclopharm (ASX: CYC) has received an operational boost with its flagship Technegas product named as the focus of a new clinical trial costing around A$387,000 seeking to develop better tools to diagnose and manage patients suffering from asthma and chronic obstructive pulmonary disease (COPD). The World Health Organisation (WHO) rates COPD as the […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.